• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-K filed by AirSculpt Technologies Inc.

    3/16/26 6:54:56 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care
    Get the next $AIRS alert in real time by email
    NT 10-K 1 airs-march2026xform12bx25f.htm NT 10-K Document

     
     

    U.S. SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 12b-25

    NOTIFICATION OF LATE FILING

    ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR     
     
    For period ended: December 31, 2025
     
    ☐
    Transition Report on Form 10-K
    ☐Transition Report on Form 20-F
    ☐Transition Report on Form 11-K
    ☐Transition Report on Form 10-Q
     
    For the Transition Period Ended: N/A
     
    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
     
    PART I - REGISTRANT INFORMATION
     
    Full Name of Registrant:
    AirSculpt Technologies, Inc.
    Former Name if Applicable:
    N/A
    Address of Principal Executive Office (Street and Number):
    1111 Lincoln Road, Suite 802
    City, State and Zip Code:
    Miami Beach, Florida 33139



     
    PART II - RULES 12b-25(b) AND (c)
     
    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
     
    (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
     
    ☒
    (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
     
    (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached, if applicable.
     
    PART III - NARRATIVE
     
    AirSculpt Technologies, Inc. (the “Company”) has determined that it is unable, without unreasonable effort or expense, to file its annual report on Form 10-K for the fiscal year ended December 31, 2025 (the “Annual Report”) by the March 16, 2026 filing deadline for accelerated filers (the “Annual Report Deadline”). The Company requires additional time to finalize the Annual Report and related audited financial statements due to the classification of inter-company transactions and balances. The Company intends to file the Annual Report as soon as practicable and currently anticipates filing the Annual Report within the fifteen-day grace period provided by Rule 12b-25 under the Securities Exchange Act of 1934, as amended; however, there can be no assurance with respect to the timing of completion of the Annual Report filing.
     
    PART IV - OTHER INFORMATION
     
    (1) Name and telephone number of person to contact in regard to this notification:
     
    Brent Wadman406321-0017
    (Name)(Area Code)(Telephone Number)
     
    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
     
    Yes ☒ No ☐
     
    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
     
    Yes ☐ No ☒
     
    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.




    Cautionary Statement Concerning Forward-Looking Statements

    This Form 12b-25 contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements may be identified by the use of words and phrases or variations of such words and phrases such as “plan,” “target,” “anticipate,” “believe,” “estimate,” “intend,” “expect,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements within this Form 12b-25 include, without limitation, statements regarding the anticipated timing of the filing of the Annual Report. All forward-looking statements herein are based upon information available to the Company as of the date hereof and speak only as of the date hereof, and, except as required by law, the Company undertakes no duty or obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are subject to risks and uncertainties, including the failure of the Company to file the Annual Report prior to the fifteenth calendar day following the Annual Report Deadline. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond the Company’s control and which could materially affect results. Additional risks related to the Company may be found in the periodic and current reports filed with the Securities and Exchange Commission (the “SEC”) by the Company, including the Company’s annual report on Form 10-K for the year ended December 31, 2024, which are available on the SEC’s website at www.sec.gov.





    AirSculpt Technologies, Inc.
    (Name of Registrant as Specified in Charter)
     
    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
     
    Date: March 16, 2026
    By:
    /s/ Brent Wadman
    Brent Wadman
    General Counsel and Corporate Secretary
     


    Get the next $AIRS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIRS

    DatePrice TargetRatingAnalyst
    10/17/2024Neutral
    BTIG Research
    5/14/2024$8.25 → $5.00Outperform → Market Perform
    Leerink Partners
    11/11/2022$4.00Overweight → Neutral
    Piper Sandler
    6/16/2022$17.00 → $8.50Overweight → Equal-Weight
    Morgan Stanley
    11/23/2021$18.00Outperform
    Raymond James
    11/23/2021$17.00Overweight
    Morgan Stanley
    11/23/2021$26.00Outperform
    SVB Leerink
    11/23/2021$22.00Overweight
    Piper Sandler
    More analyst ratings

    $AIRS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Chernett Jorey bought $257,211 worth of shares (105,848 units at $2.43), increasing direct ownership by 2% to 6,592,059 units (SEC Form 4)

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    3/16/26 6:43:51 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    Large owner Chernett Jorey bought $91,200 worth of shares (45,600 units at $2.00), increasing direct ownership by 0.72% to 6,398,211 units (SEC Form 4)

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    3/9/26 8:40:24 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    Large owner Chernett Jorey bought $192,900 worth of shares (110,000 units at $1.75), increasing direct ownership by 2% to 6,352,611 units (SEC Form 4)

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    3/4/26 6:58:41 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CORRECTION -- AirSculpt Technologies Reports Fourth Quarter and Full Year Fiscal 2025 Results

    MIAMI BEACH, Fla., April 06, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline on April 2nd, 2026, by AirSculpt Technologies, Inc. (NASDAQ:AIRS), please note that the Company determined that a one-time non-cash adjustment related to the closure of its London facility was inaccurate in the calculation of Adjusted EBITDA, Adjusted EBITDA Margin, and Adjusted Net (Loss)/Income. The updated release reflects the updated figures. AirSculpt Technologies, Inc. (NASDAQ:AIRS)("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced results for the fourth quarter and twelve months ended December 31, 2025. Yogi Jashnani, Chief Execu

    4/6/26 6:30:00 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    AirSculpt Technologies Reports Fourth Quarter and Full Year Fiscal 2025 Results

    MIAMI BEACH, Fla., April 02, 2026 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced results for the fourth quarter and twelve months ended December 31, 2025. Yogi Jashnani, Chief Executive Officer, stated: "In the fourth quarter, we delivered sequential improvement in same store sales versus the first nine months of the year and adjusted EBITDA ahead of the prior year period," stated Yogi Jashnani, Chief Executive Officer. "During 2025, we took significant steps to enhance our business approach and team. We added talent, improved business processes, implemented a new go-

    4/2/26 6:30:00 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    AirSculpt Technologies Announces Fourth Quarter and Fiscal Year 2025 Earnings Release Date and Conference Call

    MIAMI BEACH, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. ("AirSculpt") (NASDAQ:AIRS) an industry leader and provider of premium body contouring procedures, today announced it will report fourth quarter and fiscal year 2025 financial results before market open on Thursday, April 2, 2026, to be followed by a conference call on the same day at 8:30 a.m. Eastern Time. The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 13758597 or by clicking this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the investor relations s

    3/31/26 5:09:21 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    SEC Filings

    View All

    Amendment: AirSculpt Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K/A - Airsculpt Technologies, Inc. (0001870940) (Filer)

    4/6/26 6:32:59 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form 10-K/A filed by AirSculpt Technologies Inc.

    10-K/A - Airsculpt Technologies, Inc. (0001870940) (Filer)

    4/6/26 6:32:22 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    AirSculpt Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Airsculpt Technologies, Inc. (0001870940) (Filer)

    4/2/26 6:31:49 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on AirSculpt Technologies

    BTIG Research initiated coverage of AirSculpt Technologies with a rating of Neutral

    10/17/24 7:13:51 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    AirSculpt Technologies downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded AirSculpt Technologies from Outperform to Market Perform and set a new price target of $5.00 from $8.25 previously

    5/14/24 7:53:44 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    AirSculpt Technologies downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded AirSculpt Technologies from Overweight to Neutral and set a new price target of $4.00

    11/11/22 3:44:11 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chernett Jorey

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    4/6/26 9:34:45 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Chernett Jorey

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    3/25/26 1:43:15 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Chernett Jorey

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    3/23/26 9:33:39 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by AirSculpt Technologies Inc.

    SC 13G/A - Airsculpt Technologies, Inc. (0001870940) (Subject)

    11/8/24 8:42:05 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G/A filed by AirSculpt Technologies Inc. (Amendment)

    SC 13G/A - Airsculpt Technologies, Inc. (0001870940) (Subject)

    2/14/24 1:11:48 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G filed by AirSculpt Technologies Inc.

    SC 13G - Airsculpt Technologies, Inc. (0001870940) (Subject)

    4/27/23 9:49:49 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    Financials

    Live finance-specific insights

    View All

    CORRECTION -- AirSculpt Technologies Reports Fourth Quarter and Full Year Fiscal 2025 Results

    MIAMI BEACH, Fla., April 06, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline on April 2nd, 2026, by AirSculpt Technologies, Inc. (NASDAQ:AIRS), please note that the Company determined that a one-time non-cash adjustment related to the closure of its London facility was inaccurate in the calculation of Adjusted EBITDA, Adjusted EBITDA Margin, and Adjusted Net (Loss)/Income. The updated release reflects the updated figures. AirSculpt Technologies, Inc. (NASDAQ:AIRS)("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced results for the fourth quarter and twelve months ended December 31, 2025. Yogi Jashnani, Chief Execu

    4/6/26 6:30:00 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    AirSculpt Technologies Reports Fourth Quarter and Full Year Fiscal 2025 Results

    MIAMI BEACH, Fla., April 02, 2026 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced results for the fourth quarter and twelve months ended December 31, 2025. Yogi Jashnani, Chief Executive Officer, stated: "In the fourth quarter, we delivered sequential improvement in same store sales versus the first nine months of the year and adjusted EBITDA ahead of the prior year period," stated Yogi Jashnani, Chief Executive Officer. "During 2025, we took significant steps to enhance our business approach and team. We added talent, improved business processes, implemented a new go-

    4/2/26 6:30:00 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    AirSculpt Technologies Announces Fourth Quarter and Fiscal Year 2025 Earnings Release Date and Conference Call

    MIAMI BEACH, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. ("AirSculpt") (NASDAQ:AIRS) an industry leader and provider of premium body contouring procedures, today announced it will report fourth quarter and fiscal year 2025 financial results before market open on Thursday, April 2, 2026, to be followed by a conference call on the same day at 8:30 a.m. Eastern Time. The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 13758597 or by clicking this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the investor relations s

    3/31/26 5:09:21 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    Leadership Updates

    Live Leadership Updates

    View All

    AirSculpt Technologies Names Yogi Jashnani Chief Executive Officer

    MIAMI BEACH, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS) ("AirSculpt" or the "Company"), an industry leader and provider of premium body contouring procedures, today announced the appointment of Yogi Jashnani as Chief Executive Officer ("CEO") and a member of the Board of Directors. He succeeds Dennis Dean, Interim Chief Executive Officer and Chief Financial Officer who will continue as Chief Financial Officer, all effective January 7, 2025. A highly-talented, results oriented executive with an accomplished career spanning more than two decades, Mr. Jashnani has architected successful transformations for public and private companies in the aesthetics

    12/17/24 6:45:00 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care